In vivo prophylactic and therapeutic efficacy of C12G6 in mice

Slides:

Advertisements

Similar presentations

Fibroblast activation in WT and NFATc2-deficient mice.

Advertisements

In vivo prophylactic and therapeutic efficacy of C12G6 in mice

Antitumor effect of local cancer immunotherapy treatment toward distant B16F10 tumors. Antitumor effect of local cancer immunotherapy treatment toward.

Specific depletion of CD4-DTR–derived CD4 T cells.

Fig. 7 BRD0705 impairs colony formation in AML cell lines and patient cells and shows in vivo efficacy in multiple AML mouse models. BRD0705 impairs colony.

Three different types of transfer functions with a codomain of [0,1].

Fig. 7. Inhibitory mechanisms of C12G6.

Fig. 4. Improved tumor response to docetaxel in TNBC and trastuzumab in HER2-amplified PDX models with the addition of S Improved tumor response.

Comparison of therapeutic efficacies of C12G6 and other bnAbs in mice

Fig. 4. Efficacy of C12G6 compared with and in combination with oseltamivir in mice. Efficacy of C12G6 compared with and in combination with oseltamivir.

Fig. 5. Prophylactic and therapeutic efficacy of C12G6 in ferrets.

Fig. 7 Correlation of NHP and human ISGs.

T-bethi MP cells produce IFN-γ in response to IL-12.

Fig. 6 In utero injection of inflammatory cytokines or adoptive transfer of activated T cells leads to pregnancy loss. In utero injection of inflammatory.

Fig. 1 Movement percepts for all participants.

Fig. 4. Peanut-specific TH2A cells are specifically targeted during immunotherapy. Peanut-specific TH2A cells are specifically targeted during immunotherapy.

Fig. 5 Quantitative assessment of the efficacy of the tissue-engineered implant to heal the TMJ disc defect. Quantitative assessment of the efficacy of.

Antitumor effect of local cancer immunotherapy treatment in various tumor models. Antitumor effect of local cancer immunotherapy treatment in various tumor.

CXCR5+/+ TFH cells are essential for the generation of LCMV-neutralizing antibodies and clearance of a persistent LCMV infection. CXCR5+/+ TFH cells are.

Cell viability tests. Cell viability tests. SEM images of (A) MC3T3-E1 cells and (B) MSCs on days 1, 3, and 5 of culture. (C) Survival rates of MC3T3-E1.

Tumor control by necroptotic cells requires BATF3+cDC1 and CD8+leukocytes. Tumor control by necroptotic cells requires BATF3+cDC1 and CD8+leukocytes. (A)

Fig. 1. MSCs undergo in vivo apoptosis after infusion without affecting immunosuppression. MSCs undergo in vivo apoptosis after infusion without affecting.

Fig. 3 M7824 inhibits tumor growth and metastasis and provides long-term antitumor immunity. M7824 inhibits tumor growth and metastasis and provides long-term.

Fig. 2 Preserved long-term functionality of the TEHVs over 1-year follow-up as assessed by ICE and cardiac MRI flow measurements. Preserved long-term functionality.

Non–viral Ag–specific CTLs dampen inflammation in a mouse model of viral meningitis. Non–viral Ag–specific CTLs dampen inflammation in a mouse model of.

Fig. 3 Liver stiffness and NT-proBNP concentration after treatment with miridesap followed by dezamizumab. Liver stiffness and NT-proBNP concentration.

In vivo release of doxycycline hyclate from the GRS in a swine model

Fig. 5. In vivo characterization of adipogenesis by CT.

Genetic EGFR ablation in K-RAS–mutated lung AC reduces tumor growth

Vaccine MN confer protective innate and adaptive immunity.

Fig. 3 NK cells are enriched in ICB-sensitive tumors in mouse models and patients and are required for response. NK cells are enriched in ICB-sensitive.

Fig. 1 Product lifetime distributions for the eight industrial use sectors plotted as log-normal probability distribution functions (PDF). Product lifetime.

CypD-deficient mice are susceptible to Mtb infection.

Fig. 1. CAR4 and CAR8 cells demonstrate in vitro and in vivo antileukemic efficacy. CAR4 and CAR8 cells demonstrate in vitro and in vivo antileukemic efficacy.

Fig. 1 Inbred mouse strains carrying monoclonal tumors display a symmetrical yet disparate response to ICB, associated with a distinctive gene signature.

Fig. 4 Rational therapeutic modulation of the tumor microenvironment sensitizes tumors to ICB. Rational therapeutic modulation of the tumor microenvironment.

Fig. 2 Inflammatory pathways with STAT1 as a key regulator are enriched in ICB responsive tumors in mouse models and patients. Inflammatory pathways with.

Fig. 2 In situ vaccination of CpG in combination with anti-OX40 antibody cures established local and distant tumors. In situ vaccination of CpG in combination.

Fig. 5 Treatment with BMS (PO BID) protects from wasting and colitis in two SCID mouse models. Treatment with BMS (PO BID) protects from.

A multimechanistic antibody targeting the receptor binding site potently cross-protects against influenza B viruses by Chenguang Shen, Junyu Chen, Rui.

Fig. 2 L. lactis–derived lactic acid antagonizes V

Fig. 2 Extended local release of agonists of innate immunity prevents tumor recurrence and eliminates distal metastases. Extended local release of agonists.

Fig. 3 Local Maraba treatment of TNBC tumors provides long-term systemic protection. Local Maraba treatment of TNBC tumors provides long-term systemic.

Fig. 1. The HCN channel blocker ivabradine (IVA) is analgesic in a mouse model of type 1 diabetes. The HCN channel blocker ivabradine (IVA) is analgesic.

PD and efficacy of AZD4785 in KRAS mutant lung cancer xenograft models

Fig. 6 Multivalent DNA vaccine and protein antigen delivery by T4-AAV nanoparticles. Multivalent DNA vaccine and protein antigen delivery by T4-AAV nanoparticles.

Pharmacological targeting of CDs promotes response to KRASG12C inhibition in vivo. Pharmacological targeting of CDs promotes response to KRASG12C inhibition.

Fig. 2 Effect of CSF sTREM2– and CSF sTREM2–to–p-tau181 ratio on changes in cognition. Effect of CSF sTREM2– and CSF sTREM2–to–p-tau181 ratio on changes.

Fig. 2 NDR2-deficient mice are more vulnerable to RNA viral infection.

Fig. 5. Vascularization of human liver seed grafts.

Fig. 2 Neonatal ZIKV infection induces seizures in young mice and increases susceptibility to chemically induced seizures in adult mice. Neonatal ZIKV.

Fig. 6 Antitumor effect on tumor growth and pulmonary metastasis of CSSD-9 in vivo. Antitumor effect on tumor growth and pulmonary metastasis of CSSD-9.

Fig. 3 Viral loads and viral DNA in anti-α4β7 antibody–treated rhesus macaques that initiated ART during chronic SIVmac251 infection (study 2). Viral loads.

Fig. 1 Study design and antibody pharmacokinetics.

Fig. 5. High burdens of AA signature mutations and predicted immunogenicity in Taiwan HCCs. High burdens of AA signature mutations and predicted immunogenicity.

IL-33 is not critical for initiation of allergic airways disease phenotype. IL-33 is not critical for initiation of allergic airways disease phenotype.

Fig. 3 Comparisons of NDVI trends over the globally vegetated areas from 1982 to Comparisons of NDVI trends over the globally vegetated areas from.

Fig. 5 In vivo autologous self-targeting efficacy of DR-KO tumor cells co-engineered with a secretable DRL and a suicide system. In vivo autologous self-targeting.

Fibroblast activation in WT and NFATc2-deficient mice.

Fig. 6. Combinatorial VCPI and OV M1 treatment is efficacious in vivo and ex vivo. Combinatorial VCPI and OV M1 treatment is efficacious in vivo and ex.

Fig. 3 Superiority of BAFF-R versus CD19-CAR T cells in a Burkitt lymphoma model is not due to greater tumor antigen density. Superiority of BAFF-R versus.

Fig. 5 Topical vaginal application of DECON on alternate days is as effective as daily systemic ACV dosing. Topical vaginal application of DECON on alternate.

Fig. 1 Isopropanol tolerance variation among E. faecium isolates.

Fig. 4 Gallium increases P. aeruginosa sensitivity to peroxides.

Fig. 3 Ect2 gene inactivation lowers cardiomyocyte endowment and is lethal in mice. Ect2 gene inactivation lowers cardiomyocyte endowment and is lethal.

Fig. 6 Pharmacologic alterations of β-AR signaling regulate cardiomyocyte abscission and endowment. Pharmacologic alterations of β-AR signaling regulate.

PD and efficacy of AZD4785 in a KRAS wild-type lung cancer PDX model

Fig. 3. Effects of SFN in mice with diet-induced diabetes.

Fig. 3 Evaluation of PTMAO immunogenicity.

CCR6 is dispensable for expansion of innate TCRαβ+ cells in oral candidiasis. CCR6 is dispensable for expansion of innate TCRαβ+ cells in oral candidiasis.

Presentation transcript:

Fig. 2. In vivo prophylactic and therapeutic efficacy of C12G6 in mice. In vivo prophylactic and therapeutic efficacy of C12G6 in mice. (A to C) Prophylactic efficacy of C12G6 against lethal challenge with 25 MLD50 (50% mouse lethal dose) of MA-B/Florida/4/2006 (A), MA-B/Brisbane/60/2008 (B), or MA-B/Lee/1940 virus (C). The survival curves of BALB/c mice (n = 5 per group) treated with C12G6 (5, 1.7, 0.6, 0.2, or 0.06 mg/kg) or C5G6 (20 mg/kg) 1 day before lethal challenge are shown. (D to F) For the therapeutic groups, survival curves for BALB/c mice (n = 5 per group) that received C12G6 (10, 5, 1, or 0.2 mg/kg) or C5G6 (20 mg/kg) 1 day after lethal challenge with 25 MLD50 of MA-B/Florida/4/2006 (D), MA-B/Brisbane/60/2008 (E), or MA-B/Lee/1940 (F) virus are shown. (G and H) The virus titers in the lungs of the mice treated with C12G6 (5 mg/kg) prophylactically (G) or C12G6 (10 mg/kg) therapeutically (H) were determined on days 3 and 6 after infection. The control IgG is C5G6. The black bars indicate mean values. The log-rank test was used to assess the significance (*P < 0.05) of survival outcome, and the t test was used to determine the significance of virus titers in the lungs compared to the control IgG–treated group. *P < 0.05 and ***P < 0.001. TCID50, median tissure culture infectious dose. Chenguang Shen et al., Sci Transl Med 2017;9:eaam5752 Copyright © 2017 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works